The 2026 Bundibugyo Ebola Epidemic: A New Chapter in an Old Story

By Majid Sadigh, MD

The Bundibugyo epidemic reminds us that preparedness is tested not by familiar threats, but by the ones we least expect.

Introduction

On 15 May 2026, the Ministry of Health of the Democratic Republic of the Congo (DRC) announced an outbreak of Ebola virus disease in Ituri Province. Laboratory testing identified the causative agent as Bundibugyo ebolavirus, a relatively uncommon member of the Ebola virus family that has been responsible for only two previously recognized outbreaks. Within days, cases were identified in neighboring Uganda, prompting the World Health Organization (WHO) to declare a Public Health Emergency of International Concern (PHEIC).

Although Ebola outbreaks have become familiar to the global public health community, the current epidemic is different in several important ways. It involves a virus for which no licensed vaccine exists, no proven virus-specific therapy is available, and for which relatively little operational experience has accumulated compared with the far more common Zaire ebolavirus. Equally important, the outbreak appears to have expanded for weeks before recognition, raising concerns that some of the lessons learned from earlier Bundibugyo outbreaks may not have been fully incorporated into routine preparedness systems.

The Forgotten Ebola Virus

When most healthcare professionals think of Ebola virus disease, they think of Zaire ebolavirus, the species responsible for the devastating West African epidemic of 2014–2016 and most recent outbreaks in Central Africa. Bundibugyo ebolavirus is far less common.

The virus was first recognized in 2007 during an outbreak in Bundibugyo District in western Uganda. Patients presented with clinical features strongly suggestive of Ebola virus disease, yet available laboratory tests repeatedly failed to identify either Zaire ebolavirus or Sudan ebolavirus, the two Ebola species known to circulate in the region at that time.

Investigators were confronted with a puzzling situation. The disease behaved like Ebola, but the laboratory results did not fit. Only after more extensive molecular testing and genetic sequencing was a previously unknown Ebola species identified. The newly discovered virus was named Bundibugyo ebolavirus after the district where the outbreak occurred.

The outbreak ultimately resulted in 149 cases and 37 deaths, corresponding to a case-fatality rate of approximately 25%, substantially lower than that observed in many outbreaks caused by Zaire ebolavirus.

A second outbreak occurred in 2012 in Isiro, Oriental Province, in northeastern DRC. This outbreak involved 57 confirmed and probable cases and 29 deaths. Using the combined confirmed and probable case count, the overall mortality among reported cases was approximately 51%, substantially higher than the 25% observed during the 2007 outbreak in Uganda. Although considerably smaller than the 2007 outbreak, it reinforced several important lessons: the need for broad diagnostic capacity, rapid molecular characterization of unusual pathogens, strong surveillance systems, and early community engagement.

Ironically, nearly two decades later, some of these same challenges appear to have resurfaced.

Recognition of the Current Epidemic

The current outbreak was officially declared by the DRC Ministry of Health on 15 May 2026 after laboratory confirmation of Bundibugyo ebolavirus in samples collected from patients in Ituri Province.

The identity of the true index case has not been definitively established. However, according to WHO outbreak investigations, the earliest currently recognized suspected case was a healthcare worker from Ituri Province. The individual developed fever, hemorrhagic manifestations, vomiting, and profound malaise on 24 April 2026 and subsequently died at a medical center in Bunia. Retrospective epidemiologic investigation later linked this case to the outbreak that was officially recognized on 15 May 2026. The possibility that earlier, unrecognized cases occurred remains under investigation.

By the time the outbreak was announced, authorities had already identified approximately 100 suspected cases and 30 deaths. These numbers suggested that transmission had been occurring for several weeks before recognition and that multiple transmission chains were already established.

According to investigators involved in the response, blood samples from some of the earliest suspected cases were sent to Kinshasa and initially tested using assays designed primarily to detect Zaire ebolavirus, the species responsible for most previous Ebola outbreaks in the DRC. When these tests proved negative, further investigation was delayed. Only after broader filovirus testing and genomic sequencing were performed was Bundibugyo ebolavirus identified as the causative agent. The delay is particularly striking given the region's prior experience with both Bundibugyo and Sudan ebolavirus outbreaks and the availability of multiplex molecular assays capable of detecting multiple Ebola virus species simultaneously.

If confirmed in future reports, this would represent a remarkable historical parallel. The same challenge that contributed to the discovery of Bundibugyo virus in Uganda in 2007—the inability of existing diagnostic systems to recognize a genetically distinct Ebola species—may also have contributed to delayed recognition of the current epidemic. The issue may not have been the absence of appropriate diagnostic tools, but rather the failure to deploy them early enough. Preparedness is measured not only by what technologies are available, but by how effectively they are used when an outbreak begins.

The lesson is clear: outbreak preparedness must focus not only on common and familiar pathogens but also on their less common relatives.

Why WHO Acted Quickly

Only two days after the outbreak was declared, WHO Director-General Tedros Adhanom Ghebreyesus determined that the epidemic constituted a Public Health Emergency of International Concern (PHEIC).

The decision reflected several concerns. First, transmission had clearly been occurring for an extended period before recognition. Second, imported cases had already been identified in Uganda. Third, the outbreak was unfolding in one of the most challenging public health environments in Africa. Finally, there were no licensed vaccines or approved antiviral therapies specifically available for Bundibugyo virus disease.

The declaration also attracted attention because it was made before formal consultation with the Emergency Committee established under the International Health Regulations. WHO subsequently convened the committee after the declaration. The unusually rapid action reflected concerns regarding delayed recognition of the outbreak, evidence of cross-border spread, and the absence of licensed vaccines or virus-specific therapies. While some observers questioned the process, others viewed the decision as an effort to avoid the delays in international mobilization that have complicated responses to previous public health emergencies.

The declaration was not intended to signal an impending pandemic. Rather, it was designed to mobilize international attention, funding, personnel, and logistical support before the epidemic expanded further.

A Perfect Storm in Ituri

The outbreak is occurring in a region where disease control is extraordinarily difficult.

Ituri Province has experienced years of armed conflict, population displacement, poverty, and political instability. Many communities are remote and difficult to access. Transportation infrastructure is limited, healthcare resources are scarce, and insecurity frequently disrupts public health operations.

These conditions have complicated previous Ebola responses in eastern Congo. During earlier outbreaks, treatment centers were attacked, healthcare workers threatened, and response activities interrupted by violence. In some instances, Ebola treatment units were vandalized or destroyed.

Community mistrust remains another major obstacle. Surveys conducted after previous outbreaks demonstrated that some residents in affected communities continued to believe that Ebola was exaggerated, fabricated, or politically motivated. Even if such views are held by only a small proportion of the population, they can significantly undermine contact tracing, isolation measures, safe burial practices, and vaccination campaigns.

Controlling Ebola ultimately requires trust.

A Different Ebola Problem

One of the greatest challenges facing responders is that Bundibugyo virus differs substantially from the Zaire strain for which modern vaccines and therapies were developed.

The recombinant vesicular stomatitis virus vaccine (rVSV-ZEBOV), which transformed Ebola control efforts during outbreaks caused by Zaire ebolavirus, was specifically designed against the Zaire glycoprotein and is not expected to provide reliable protection against Bundibugyo virus.

Similarly, the monoclonal antibody therapies Inmazeb (REGN-EB3) and Ebanga (mAb114), which significantly improved survival during recent Zaire Ebola outbreaks, were developed and validated against Zaire ebolavirus infections.

The situation is similar for Sudan ebolavirus. During the Sudan Ebola outbreak in Uganda in 2022, no licensed vaccine or proven therapeutic was available, underscoring the challenge posed by Ebola species other than Zaire.

Researchers are now pursuing multivalent vaccines and broadly neutralizing monoclonal antibodies capable of protecting against multiple Ebola species simultaneously. Several candidate products are under development, but none is yet available for routine use.

Consequently, supportive care remains the cornerstone of management. Early diagnosis, aggressive fluid replacement, electrolyte correction, treatment of secondary infections, and meticulous infection-prevention measures remain the most effective tools currently available.

Current Situation

As of the end of May 2026, WHO had reported more than 1,100 suspected cases, more than 265 laboratory-confirmed cases, over 220 suspected deaths, and 45 confirmed deaths. Cases have been documented in Ituri, North Kivu, and South Kivu provinces, while Uganda has reported a total of 9 confirmed cases and 1 death. Most Ugandan cases occurred in and around Kampala, with several linked to travel from the DRC. No sustained community transmission has yet been documented.

Although these numbers remain subject to revision as investigations continue, they suggest that the current outbreak may already be the largest Bundibugyo ebolavirus epidemic ever recorded.

Whether transmission has peaked remains uncertain. WHO, Médecins Sans Frontières, and regional public health agencies have emphasized that the epidemic is still evolving and that surveillance, contact tracing, laboratory testing, and community engagement must continue to expand.

The marked variation in mortality observed across Bundibugyo outbreaks—from approximately 25% in Uganda in 2007 to 51% in Isiro in 2012—suggests that outcomes are influenced not only by viral biology but also by the timeliness of diagnosis, access to supportive care, and the strength of local health systems.

Why This Will Not Become a Pandemic

The declaration of a PHEIC has inevitably generated comparisons with COVID-19. Such comparisons are understandable but biologically misleading.

Ebola virus is a highly lethal pathogen, but it is not a highly transmissible one.

Unlike respiratory viruses, Ebola requires direct contact with infected body fluids. Patients are generally not contagious before symptom onset and rapidly become debilitated once symptomatic. Transmission therefore occurs primarily among family members, caregivers, healthcare workers, and participants in funeral rituals.

For these reasons, the current outbreak is unlikely to become a global pandemic. It is more appropriately viewed as an expanding regional epidemic with potentially devastating consequences for affected communities.

The greatest threat is not worldwide spread. The greatest threat is continued transmission in a region already burdened by conflict, poverty, displacement, and limited healthcare resources.

Lessons from Three Outbreaks

Taken together, the Bundibugyo outbreaks of 2007, 2012, and 2026 tell a consistent story.

The 2007 outbreak taught the importance of broad diagnostic capability and genomic surveillance. The 2012 outbreak reinforced the value of rapid response and community engagement. The current epidemic demonstrates that these lessons remain as relevant as ever.

The virus itself has changed little. What determines the size and impact of an outbreak is often not the biology of the pathogen but the strength of the systems confronting it.

Nearly fifty years after Ebola virus was first discovered in Yambuku, the current epidemic serves as a reminder that scientific advances alone are insufficient. Vaccines, therapeutics, and molecular diagnostics are powerful tools, but they cannot substitute for strong public health infrastructure, community trust, and sustained international solidarity.

Viruses exploit biology. Epidemics exploit fragile systems.

The Bundibugyo epidemic reminds us that preparedness is tested not by familiar threats, but by the ones we least expect. Whether the lessons from 2007, 2012, and now 2026 will finally be translated into lasting preparedness remains one of the most important questions in global health.

---

Author Bio

Majid Sadigh, MD, is the founding director of the Nuvance Health Global Health Academy. A physician-educator and humanitarian, he has devoted his career to advancing equitable global partnerships that train future leaders in medicine, education, and service.